ReviewBioMed research international2014
A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer.Yonsei medical journal · 2019Article
- Clinical association between pre-treatment levels of plasma fibrinogen and bone metastatic burden in newly diagnosed prostate cancer patients.Chinese medical journal · 2019Article
- Potential biological and clinical benefit of prostate-directed interventions in patients with metastatic prostate cancer.Annals of translational medicine · 2019Article
- Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.Yonsei medical journal · 2018Review
- NMR-based metabolomics studies of human prostate cancer tissue.Metabolomics : Official journal of the Metabolomic Society · 2018Review
- Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?Prostate cancer · 2018Review
- Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer.Prostate international · 2017Article
- [When is a nonsurgical approach possible for metastatic primary tumors and lymph node metastases of the urinary bladder and prostate?]Der Urologe. Ausg. A · 2017Review
- Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome.Ecancermedicalscience · 2017Article
- Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.Clinical Medicine Insights. Oncology · 2017Article
- Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.Nature reviews. Urology · 2017Review
- Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.Translational oncology · 2016Review
- Is it really an abscess? An unusual case of metastatic stromal cell sarcoma of the prostate.International journal of surgery case reports · 2015Article
- Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To provide an overview of the currently available literature regarding local control of primary tumor and oligometastases in metastatic prostate cancer and salvage lymph node dissection of clinical lymph node relapse after curative treatment of prostate cancer. Evidence Acquisition. A systematic literature search was conducted in 2014 to identify abstracts, original articles, review articles, research articles, and editorials relevant to the local control in metastatic prostate cancer. Evidence Synthesis. Local control of primary tumor in metastatic prostate cancer remains experimental with low level of evidence. The concept is supported by a growing body of genetic and molecular research as well as analogy with other cancers. There is only one retrospective observational population based study showing prolonged survival. To eradicate oligometastases, several options exist with excellent local control rates. Stereotactic body radiotherapy is safe, well tolerated, and efficacious treatment for lymph node and bone lesions. Both biochemical and clinical progression are slowed down with a median time to initiate ADT of 2 years. Salvage lymph node dissection is feasible in patients with clinical lymph node relapse after local curable treatment. Conclusion. Despite encouraging oncologic midterm results, a complete cure remains elusive in metastatic prostate cancer patients. Further advances in imaging are crucial in order to rapidly evolve beyond the proof of concept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.